{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:56:53Z","timestamp":1790639813828,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Allergy Asthma Rep"],"DOI":"10.1007\/s11882-026-01298-x","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T07:04:28Z","timestamp":1790579068000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypersensitivity Reactions to Biologics: Advances in Diagnosis and Management"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-095X","authenticated-orcid":false,"given":"Barbara C.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1298_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16353","author":"BC Yang","year":"2024","unstructured":"Yang BC, Castells M. Medical algorithm: Diagnosis and treatment of drug hypersensitivity reactions to biologicals, 2024 update. Allergy. 2024. https:\/\/doi.org\/10.1111\/all.16353.","journal-title":"Allergy"},{"issue":"1","key":"1298_CR2","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, Qian W, Sun X, Jiang S. Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. J Hematol Oncol. 2022;15(1):143. https:\/\/doi.org\/10.1186\/s13045-022-01362-9.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1298_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11882-022-01052-z","volume":"23","author":"BC Yang","year":"2023","unstructured":"Yang BC, Castells MC. Utilizing biologics in drug desensitization. Curr Allergy Asthma Rep. 2023;23(1):1\u201311. https:\/\/doi.org\/10.1007\/s11882-022-01052-z.","journal-title":"Curr Allergy Asthma Rep"},{"issue":"1","key":"1298_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/all.14984","volume":"77","author":"S Bavbek","year":"2022","unstructured":"Bavbek S, Pagani M, Alvarez-Cuesta E, Castells M, Dursun AB, Hamadi S, et al. Hypersensitivity reactions to biologicals: An EAACI position paper. Allergy. 2022;77(1):39\u201354. https:\/\/doi.org\/10.1111\/all.14984.","journal-title":"Allergy"},{"issue":"6","key":"1298_CR5","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.jaci.2009.09.009","volume":"124","author":"PJ Brennan","year":"2009","unstructured":"Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259\u201366. https:\/\/doi.org\/10.1016\/j.jaci.2009.09.009.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1298_CR6","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJMoa074943","volume":"358","author":"CH Chung","year":"2008","unstructured":"Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358(11):1109\u201317. https:\/\/doi.org\/10.1056\/NEJMoa074943.","journal-title":"N Engl J Med"},{"issue":"6","key":"1298_CR7","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/1078155213510542","volume":"20","author":"K Keating","year":"2014","unstructured":"Keating K, Walko C, Stephenson B, O\u2019Neil BH, Weiss J. Incidence of cetuximab-related infusion reactions in oncology patients treated at the University of North Carolina Cancer Hospital. J Oncol Pharm Pract. 2014;20(6):409\u201316. https:\/\/doi.org\/10.1177\/1078155213510542.","journal-title":"J Oncol Pharm Pract"},{"issue":"8","key":"1298_CR8","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1111\/j.1398-9995.2006.01058.x","volume":"61","author":"WJ Pichler","year":"2006","unstructured":"Pichler WJ. Adverse side-effects to biological agents. Allergy. 2006;61(8):912\u201320. https:\/\/doi.org\/10.1111\/j.1398-9995.2006.01058.x.","journal-title":"Allergy"},{"issue":"2","key":"1298_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.iac.2021.12.004","volume":"42","author":"BC Yang","year":"2022","unstructured":"Yang BC, Castells MC. The who, what, where, when, why, and how of drug desensitization. Immunol Allergy Clin North Am. 2022;42(2):403\u201320. https:\/\/doi.org\/10.1016\/j.iac.2021.12.004.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"4","key":"1298_CR10","doi-asserted-by":"publisher","first-page":"e70170","DOI":"10.1002\/clt2.70170","volume":"16","author":"J Alder","year":"2026","unstructured":"Alder J, Lacy KE, Josephs DH, Spicer J, Bax HJ, Karagiannis SN, et al. AllergoOncology: emerging translational and clinical significance of basophils and mast cells in cancer. Clin Transl Allergy. 2026;16(4):e70170. https:\/\/doi.org\/10.1002\/clt2.70170.","journal-title":"Clin Transl Allergy"},{"issue":"1","key":"1298_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40521-020-00242-2","volume":"7","author":"A Akarsu","year":"2020","unstructured":"Akarsu A, Soyer O, Sekerel BE. Hypersensitivity reactions to biologicals: from bench to bedside. Curr Treat Options Allergy. 2020;7(1):71\u201383. https:\/\/doi.org\/10.1007\/s40521-020-00242-2.","journal-title":"Curr Treat Options Allergy"},{"issue":"3","key":"1298_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5415\/apallergy.0000000000000233","volume":"16","author":"D Fetarayani","year":"2026","unstructured":"Fetarayani D, Kahdina M, Sandra DY, Sutanto H. Drug-induced anaphylaxis: Molecular pathophysiology, diagnosis, and management. Asia Pac Allergy. 2026;16(3):181\u201397. https:\/\/doi.org\/10.5415\/apallergy.0000000000000233.","journal-title":"Asia Pac Allergy"},{"key":"1298_CR13","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","volume":"9","author":"G Porebski","year":"2018","unstructured":"Porebski G, Kwiecien K, Pawica M, Kwitniewski M, Mas-related G, protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions. Front Immunol. 2018;9:3027. https:\/\/doi.org\/10.3389\/fimmu.2018.03027.","journal-title":"Front Immunol"},{"key":"1298_CR14","doi-asserted-by":"publisher","first-page":"676354","DOI":"10.3389\/fimmu.2021.676354","volume":"12","author":"BD McNeil","year":"2021","unstructured":"McNeil BD. MRGPRX2 and Adverse Drug Reactions. Front Immunol. 2021;12:676354. https:\/\/doi.org\/10.3389\/fimmu.2021.676354.","journal-title":"Front Immunol"},{"issue":"4","key":"1298_CR15","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.anai.2025.07.018","volume":"135","author":"J Caiado","year":"2025","unstructured":"Caiado J, Castells MC. Update on desensitization to chemotherapeutics and biologicals. Ann Allergy Asthma Immunol. 2025;135(4):374\u201382. https:\/\/doi.org\/10.1016\/j.anai.2025.07.018.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1298_CR16","doi-asserted-by":"publisher","first-page":"1684307","DOI":"10.3389\/fimmu.2025.1684307","volume":"16","author":"DT de Bruin","year":"2025","unstructured":"de Bruin DT, Jansen MAA, Pereira DR, van Schijndel L, Klaassen ES, Otto ME, et al. POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study. Front Immunol. 2025;16:1684307. https:\/\/doi.org\/10.3389\/fimmu.2025.1684307.","journal-title":"Front Immunol"},{"issue":"3","key":"1298_CR17","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","volume":"5","author":"M Picard","year":"2017","unstructured":"Picard M, Galvao VR. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2017;5(3):600\u20139. https:\/\/doi.org\/10.1016\/j.jaip.2016.12.001.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"1298_CR18","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","volume":"133","author":"JJ Lyons","year":"2014","unstructured":"Lyons JJ, Sun G, Stone KD, Nelson C, Wisch L, O\u2019Brien M, et al. Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities. J Allergy Clin Immunol. 2014;133(5):1471\u20134. https:\/\/doi.org\/10.1016\/j.jaci.2013.11.039.","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"1298_CR19","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jaci.2014.06.007","volume":"134","author":"V Sabato","year":"2014","unstructured":"Sabato V, Van De Vijver E, Hagendorens M, Vrelust I, Reyniers E, Fransen E, et al. Familial hypertryptasemia with associated mast cell activation syndrome. J Allergy Clin Immunol. 2014;134(6):1448\u2013e503. https:\/\/doi.org\/10.1016\/j.jaci.2014.06.007.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1298_CR20","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ng.3200","volume":"47","author":"RE Handsaker","year":"2015","unstructured":"Handsaker RE, Van Doren V, Berman JR, Genovese G, Kashin S, Boettger LM, et al. Large multiallelic copy number variations in humans. Nat Genet. 2015;47(3):296\u2013303. https:\/\/doi.org\/10.1038\/ng.3200.","journal-title":"Nat Genet"},{"issue":"12","key":"1298_CR21","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"Lyons JJ, Yu X, Hughes JD, Le QT, Jamil A, Bai Y, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564\u20139. https:\/\/doi.org\/10.1038\/ng.3696.","journal-title":"Nat Genet"},{"key":"1298_CR22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190701","author":"QT Le","year":"2019","unstructured":"Le QT, Lyons JJ, Naranjo AN, Olivera A, Lazarus RA, Metcalfe DD, et al. Impact of naturally forming human alpha\/beta-tryptase heterotetramers in the pathogenesis of hereditary alpha-tryptasemia. J Exp Med. 2019. https:\/\/doi.org\/10.1084\/jem.20190701.","journal-title":"J Exp Med"},{"issue":"3","key":"1298_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","volume":"38","author":"JJ Lyons","year":"2018","unstructured":"Lyons JJ. Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. Immunol Allergy Clin North Am. 2018;38(3):483\u201395. https:\/\/doi.org\/10.1016\/j.iac.2018.04.003.","journal-title":"Immunol Allergy Clin North Am"},{"issue":"6","key":"1298_CR24","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.jaip.2025.04.013","volume":"13","author":"P Korosec","year":"2025","unstructured":"Korosec P, Lyons JJ, Svetina M, Koudova M, Bittoova M, Zidarn M, et al. Hereditary alpha-tryptasemia is Associated With Anaphylaxis to Antibiotics and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2025;13(6):1449\u2013e564. https:\/\/doi.org\/10.1016\/j.jaip.2025.04.013.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1298_CR25","doi-asserted-by":"publisher","first-page":"1599358","DOI":"10.3389\/falgy.2025.1599358","volume":"6","author":"JC McMurray","year":"2025","unstructured":"McMurray JC, Schornack BJ, Villar J, George TI, Boggs NA. Utility of tryptase genotyping in the screening, diagnosis, and management of systemic mastocytosis. Front Allergy. 2025;6:1599358. https:\/\/doi.org\/10.3389\/falgy.2025.1599358.","journal-title":"Front Allergy"},{"key":"1298_CR26","doi-asserted-by":"publisher","unstructured":"Ventura MT, Giuliano AFM, Boni E, Brussino L, Buquicchio R, Conte M, et al. Gender and allergy: mechanisms, clinical phenotypes, and therapeutic response-a position paper from the societa Italiana di Allergologia, Asma ed Immunologia Clinica (SIAAIC). Int J Mol Sci. 2025;26(19). https:\/\/doi.org\/10.3390\/ijms26199605.","DOI":"10.3390\/ijms26199605"},{"issue":"4","key":"1298_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s44446-025-00031-5","volume":"33","author":"M AlGassim","year":"2025","unstructured":"AlGassim M, Alawami F, Bakhsh GH, Al-Shouli S, Alhumaid NK, Alshehri AA, et al. Towards standardized skin testing for drug-induced allergic reactions. Saudi Pharm J. 2025;33(4):26. https:\/\/doi.org\/10.1007\/s44446-025-00031-5.","journal-title":"Saudi Pharm J"},{"key":"1298_CR28","doi-asserted-by":"publisher","first-page":"1605690","DOI":"10.3389\/fphar.2025.1605690","volume":"16","author":"P Vazquez-Revuelta","year":"2025","unstructured":"Vazquez-Revuelta P, Madrigal-Burgaleta R, Ruffinelli JC, Casanovas E, Coloma A, Lleonart R. Oxaliplatin-induced type II hypersensitivity in colorectal cancer: a cohort study on clinical presentation, diagnosis, and management. Front Pharmacol. 2025;16:1605690. https:\/\/doi.org\/10.3389\/fphar.2025.1605690.","journal-title":"Front Pharmacol"},{"key":"1298_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5414\/ALX02533E","volume":"8","author":"U Jappe","year":"2024","unstructured":"Jappe U, Bergmann KC, Brinkmann F, Faihs V, Gulsen A, Klimek L, et al. Biologics in allergology and clinical immunology: Update on therapies for atopic diseases, urticaria, and angioedema and on safety aspects focusing on hypersensitivity reactions. Allergol Select. 2024;8:365\u2013406. https:\/\/doi.org\/10.5414\/ALX02533E.","journal-title":"Allergol Select"},{"issue":"2","key":"1298_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jaip.2018.07.031","volume":"7","author":"R Madrigal-Burgaleta","year":"2019","unstructured":"Madrigal-Burgaleta R, Bernal-Rubio L, Berges-Gimeno MP, Carpio-Escalona LV, Gehlhaar P, Alvarez-Cuesta E. A large single-hospital experience using drug provocation testing and rapid drug desensitization in hypersensitivity to antineoplastic and biological agents. J Allergy Clin Immunol Pract. 2019;7(2):618\u201332. https:\/\/doi.org\/10.1016\/j.jaip.2018.07.031.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1298_CR31","doi-asserted-by":"publisher","first-page":"166","DOI":"10.18176\/jiaci.0552","volume":"31","author":"J Marti-Garrido","year":"2021","unstructured":"Marti-Garrido J, Vazquez-Revuelta P, Lleonart-Bellfill R, Molina-Mata K, Munoz-Sanchez C, Madrigal-Burgaleta R. Pilot experience using drug provocation testing for the study of hypersensitivity to chemotherapy and biological agents. J Investig Allergol Clin Immunol. 2021;31(2):166\u20138. https:\/\/doi.org\/10.18176\/jiaci.0552.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"8","key":"1298_CR32","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1111\/all.16607","volume":"80","author":"M Pascal","year":"2025","unstructured":"Pascal M, Chauhan J, Knol E, Bianchini R, Castells M, De Las Vecillas L, et al. Basophil activation test: bridging allergy and oncology for diagnostic, therapeutic and prognostic applications in AllergoOncology: An EAACI position paper. Allergy. 2025;80(8):2097\u2013112. https:\/\/doi.org\/10.1111\/all.16607.","journal-title":"Allergy"},{"issue":"1","key":"1298_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/all.16296","volume":"80","author":"G Bogas","year":"2025","unstructured":"Bogas G, Ariza A, Vazquez-Revuelta P, Labella M, Madrigal-Burgaleta R, Fernandez-Santamaria R, et al. Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes. Allergy. 2025;80(1):271\u201386. https:\/\/doi.org\/10.1111\/all.16296","journal-title":"Allergy"},{"issue":"11","key":"1298_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/all.12698","volume":"70","author":"HJ Hoffmann","year":"2015","unstructured":"Hoffmann HJ, Santos AF, Mayorga C, Nopp A, Eberlein B, Ferrer M, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393\u2013405. https:\/\/doi.org\/10.1111\/all.12698","journal-title":"Allergy"},{"issue":"2","key":"1298_CR35","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaip.2015.10.007","volume":"4","author":"D Gonzalez-de-Olano","year":"2016","unstructured":"Gonzalez-de-Olano D, Morgado JM, Juarez-Guerrero R, Sanchez-Munoz L, Letellez-Fernandez J, Malon-Gimenez D, et al. Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization. J Allergy Clin Immunol Pract. 2016;4(2):338\u201340. https:\/\/doi.org\/10.1016\/j.jaip.2015.10.007","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"1298_CR36","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jaip.2016.11.006","volume":"5","author":"P Giavina-Bianchi","year":"2017","unstructured":"Giavina-Bianchi P, Galvao VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. J Allergy Clin Immunol Pract. 2017;5(3):728\u201336. https:\/\/doi.org\/10.1016\/j.jaip.2016.11.006","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1298_CR37","doi-asserted-by":"publisher","unstructured":"Berghea EC, Coman-Stanemir M, Papacocea IR. Basophil activation test in IgE-mediated wheat allergy: diagnostic and clinical applications-a narrative review. Diagnostics (Basel). 2025;15(20). https:\/\/doi.org\/10.3390\/diagnostics15202659","DOI":"10.3390\/diagnostics15202659"},{"issue":"4","key":"1298_CR38","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaip.2020.11.021","volume":"9","author":"P Vazquez-Revuelta","year":"2021","unstructured":"Vazquez-Revuelta P, Marti-Garrido J, Molina-Mata K, Lleonart-Bellfill R, Rey-Salido M, Madrigal-Burgaleta R. Delabeling patients from chemotherapy and biologics allergy: Implementing drug provocation testing. J Allergy Clin Immunol Pract. 2021;9(4):1742\u2013e51. https:\/\/doi.org\/10.1016\/j.jaip.2020.11.021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1298_CR39","doi-asserted-by":"publisher","unstructured":"Lerario A, Abati E, Sciacco M, Comi GP, Desantis V, D'Amore S, et al. Combined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease. Orphanet J Rare Dis. 2026;21(1). https:\/\/doi.org\/10.1186\/s13023-026-04385-4","DOI":"10.1186\/s13023-026-04385-4"},{"key":"1298_CR40","doi-asserted-by":"publisher","unstructured":"Alpan O, Wasserman RL, Kim T, Darter A, Shah A, Jones D, et al. Towards an FDA-cleared basophil activation test. Front Allergy. 2022;3:1009437. https:\/\/doi.org\/10.3389\/falgy.2022.1009437","DOI":"10.3389\/falgy.2022.1009437"},{"issue":"12","key":"1298_CR41","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1007\/s13555-023-01069-w","volume":"13","author":"D Koumaki","year":"2023","unstructured":"Koumaki D, Gregoriou S, Evangelou G, Katoulis A, Papadakis M, Krueger-Krasagakis SE, et al. Real-life utility of basophil activation test in the diagnosis of immediate hypersensitivity drug reactions. Dermatol Ther (Heidelb). 2023;13(12):3229\u201339. https:\/\/doi.org\/10.1007\/s13555-023-01069-w","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1298_CR42","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/all.15957","volume":"79","author":"C Mayorga","year":"2024","unstructured":"Mayorga C, Celik GE, Pascal M, Hoffmann HJ, Eberlein B, Torres MJ, et al. Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper. Allergy. 2024;79(3):580\u2013600. https:\/\/doi.org\/10.1111\/all.15957","journal-title":"Allergy"},{"key":"1298_CR43","doi-asserted-by":"crossref","unstructured":"Arasi S NM, Caimmi D, Chiera F, Dinardo G, Giannetti A, Gracci S, Mastrorilli C, Pecoraro L, Miraglia Del Giudice M, Marseglia GL, Bernardini R. Basophil activation test (BAT): Clinical and research relevance in allergy diagnostics. Ital J Pediatr Allergy Immunol. 2026:40(1):36\u201343.","DOI":"10.53151\/2531-3916\/2026-1906"},{"issue":"7","key":"1298_CR44","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1111\/all.70324","volume":"81","author":"LH Garvey","year":"2026","unstructured":"Garvey LH, Brockow K, Barbaud A, Mortz CG, Calogiuri G, Gelincik A, et al. Hypersensitivity to excipients in drugs: an EAACI position paper. Allergy. 2026;81(7):2250\u201375. https:\/\/doi.org\/10.1111\/all.70324.","journal-title":"Allergy"},{"key":"1298_CR45","doi-asserted-by":"publisher","unstructured":"Izquierdo-Dominguez A, Al-Salloom Z, Vinas M, Mullol J, Alobid I. Understanding biologics in CRSwNP: related events and insights. Curr Allergy Asthma Rep. 2026;26(1). https:\/\/doi.org\/10.1007\/s11882-026-01269-2.","DOI":"10.1007\/s11882-026-01269-2"},{"issue":"6","key":"1298_CR46","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s40265-026-02310-4","volume":"86","author":"M Cazzola","year":"2026","unstructured":"Cazzola M, Matera MG, Ora J, Calzetta L, Rogliani P. Current and emerging biologic therapies for severe asthma. Drugs. 2026;86(6):813\u201340. https:\/\/doi.org\/10.1007\/s40265-026-02310-4.","journal-title":"Drugs"},{"issue":"41","key":"1298_CR47","doi-asserted-by":"publisher","first-page":"e45143","DOI":"10.1097\/MD.0000000000045143","volume":"104","author":"BH Yoon","year":"2025","unstructured":"Yoon BH, Moon MK, Ahn HC, Yang YM. Long-term real-world effectiveness and safety of dupilumab: A retrospective observational study from a Korean tertiary hospital. Med (Baltim). 2025;104(41):e45143. https:\/\/doi.org\/10.1097\/MD.0000000000045143.","journal-title":"Med (Baltim)"},{"key":"1298_CR48","doi-asserted-by":"publisher","unstructured":"Boscia G, Spataro F, Desantis V, Solimando AG, Vacca A, Ria R, et al. Ocular side effects of dupilumab: a comprehensive overview of the literature. J Clin Med. 2025;14(7). https:\/\/doi.org\/10.3390\/jcm14072487.","DOI":"10.3390\/jcm14072487"},{"issue":"1","key":"1298_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10384-025-01299-9","volume":"70","author":"J Shoji","year":"2026","unstructured":"Shoji J, Ebihara N. Clinical characteristics and management of dupilumab-associated ocular surface disease in Japan. Jpn J Ophthalmol. 2026;70(1):1\u201317. https:\/\/doi.org\/10.1007\/s10384-025-01299-9.","journal-title":"Jpn J Ophthalmol"},{"key":"1298_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2026.04.009","author":"YT Cho","year":"2026","unstructured":"Cho YT, Chan TC, Chen WL, Chu HS, Chu CY. Reduced conjunctival goblet cells and altered tear film stability predispose atopic dermatitis patients to develop dupilumab-associated ocular surface disease and show a Th1\/innate immune response in tear fluid. Allergol Int. 2026. https:\/\/doi.org\/10.1016\/j.alit.2026.04.009.","journal-title":"Allergol Int"},{"key":"1298_CR51","doi-asserted-by":"publisher","unstructured":"Yasui K, Yashiro M. Drug-induced sarcoidosis-like reaction following IL-4\/IL-13 receptor blockade by dupilumab. Eur J Pediatr. 2026;185(6). https:\/\/doi.org\/10.1007\/s00431-026-07051-w.","DOI":"10.1007\/s00431-026-07051-w"},{"key":"1298_CR52","doi-asserted-by":"publisher","first-page":"1875748","DOI":"10.3389\/fimmu.2026.1875748","volume":"17","author":"F Fu","year":"2026","unstructured":"Fu F, Zhao Q, Ma L, Wang A, Wang Z, Xu X. Case Report: Dupilumab-associated ulcerative colitis: elucidating the pathomechanistic link between Th2 blockade and Th17 polarized intestinal inflammation. Front Immunol. 2026;17:1875748. https:\/\/doi.org\/10.3389\/fimmu.2026.1875748.","journal-title":"Front Immunol"},{"issue":"5","key":"1298_CR53","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/ACI.0000000000001102","volume":"25","author":"K Jafari","year":"2025","unstructured":"Jafari K, Calder VL. Emerging concepts in atopic dermatitis and atopic keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2025;25(5):388\u201394. https:\/\/doi.org\/10.1097\/ACI.0000000000001102.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"2","key":"1298_CR54","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1021\/acs.chemrev.4c00216","volume":"125","author":"Y Huang","year":"2025","unstructured":"Huang Y, Zhang P, Wang H, Chen Y, Liu T, Luo X. Genetic code expansion: recent developments and emerging applications. Chem Rev. 2025;125(2):523\u201398. https:\/\/doi.org\/10.1021\/acs.chemrev.4c00216.","journal-title":"Chem Rev"},{"key":"1298_CR55","doi-asserted-by":"publisher","first-page":"101078","DOI":"10.1016\/j.drup.2024.101078","volume":"74","author":"L Yang","year":"2024","unstructured":"Yang L, Bhattacharya A, Peterson D, Li Y, Liu X, Marangoni E, et al. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models. Drug Resist Updat. 2024;74:101078. https:\/\/doi.org\/10.1016\/j.drup.2024.101078.","journal-title":"Drug Resist Updat"},{"key":"1298_CR56","doi-asserted-by":"publisher","first-page":"148","DOI":"10.18632\/oncoscience.631","volume":"12","author":"CH Martins","year":"2025","unstructured":"Martins CH, Rocha JM, Portela C, Fernandes R, Caeiro C. Metastatic breast cancer with leptomeningeal carcinomatosis treated with trastuzumab deruxtecan - a case report. Oncoscience. 2025;12:148\u201355. https:\/\/doi.org\/10.18632\/oncoscience.631.","journal-title":"Oncoscience"},{"issue":"18","key":"1298_CR57","doi-asserted-by":"publisher","first-page":"e71255","DOI":"10.1002\/cam4.71255","volume":"14","author":"FAN Biteghe","year":"2025","unstructured":"Biteghe FAN, Mungra N, Malindi Z, Chalomie NET, Stanislas KA, Yasmin-Karim S, et al. The therapeutic potential of photoimmunotherapy as a safe, effective and non-toxic treatment option for superficial triple negative breast cancer. Cancer Med. 2025;14(18):e71255. https:\/\/doi.org\/10.1002\/cam4.71255.","journal-title":"Cancer Med"},{"key":"1298_CR58","doi-asserted-by":"publisher","first-page":"578075","DOI":"10.2147\/JAA.S578075","volume":"19","author":"K Kirdok","year":"2026","unstructured":"Kirdok K, Ertuna E, Ates U, Galata Z, Senturk MIT, Kural RF, et al. Safety and outcomes of rapid drug desensitization to various biologic agents: a multidisciplinary experience. J Asthma Allergy. 2026;19:578075. https:\/\/doi.org\/10.2147\/JAA.S578075.","journal-title":"J Asthma Allergy"},{"issue":"15","key":"1298_CR59","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1182\/bloodadvances.2024014903","volume":"9","author":"E Shumilov","year":"2025","unstructured":"Shumilov E, Wurm-Kuczera R, Kerkhoff A, Wang M, Melchardt T, Holtick U, et al. Safety and efficacy of glofitamab for relapsed\/refractory large B-cell lymphoma in a multinational real-world study. Blood Adv. 2025;9(15):3865\u201377. https:\/\/doi.org\/10.1182\/bloodadvances.2024014903.","journal-title":"Blood Adv"},{"key":"1298_CR60","doi-asserted-by":"publisher","first-page":"0712","DOI":"10.34133\/research.0712","volume":"8","author":"R Gu","year":"2025","unstructured":"Gu R, Shen J, Zhang J, Mao J, Ye Q. Revolutionizing autoimmune kidney disease treatment with chimeric antigen receptor-T cell therapy. Res (Wash D C). 2025;8:0712. https:\/\/doi.org\/10.34133\/research.0712.","journal-title":"Res (Wash D C)"},{"issue":"6","key":"1298_CR61","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"1298_CR62","doi-asserted-by":"publisher","first-page":"539066","DOI":"10.2147\/BTT.S539066","volume":"20","author":"B Piron","year":"2026","unstructured":"Piron B, Moreau P, Touzeau C. Teclistamab for relapsed or refractory multiple myeloma: a review of efficacy, safety, resistance mechanisms and future directions. Biologics. 2026;20:539066. https:\/\/doi.org\/10.2147\/BTT.S539066.","journal-title":"Biologics"},{"issue":"5","key":"1298_CR63","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/ACI.0000000000000940","volume":"23","author":"BC Yang","year":"2023","unstructured":"Yang BC. Biologics to treat anaphylaxis. Curr Opin Allergy Clin Immunol. 2023;23(5):370\u20135. https:\/\/doi.org\/10.1097\/ACI.0000000000000940.","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"1298_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/isrctn50499387","author":"ISRCTN_Registry","year":"2026","unstructured":"ISRCTN_Registry. Testing a new treatment to prevent severe immune reactions in people with multiple myeloma taking teclistamab. ISRCTN50499387. 2026. https:\/\/doi.org\/10.1186\/isrctn50499387.","journal-title":"ISRCTN50499387"},{"issue":"3","key":"1298_CR65","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.ygyno.2004.11.043","volume":"96","author":"AM Feldweg","year":"2005","unstructured":"Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005;96(3):824\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2004.11.043.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1298_CR66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008;122(3):574\u201380. https:\/\/doi.org\/10.1016\/j.jaci.2008.02.044.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"1298_CR67","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ygyno.2005.06.028","volume":"99","author":"CW Lee","year":"2005","unstructured":"Lee CW, Matulonis UA, Castells MC. Rapid inpatient\/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005;99(2):393\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2005.06.028.","journal-title":"Gynecol Oncol"},{"issue":"3","key":"1298_CR68","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2500\/aap.2026.47.260018","volume":"47","author":"H Kayikci","year":"2026","unstructured":"Kayikci H, Damadoglu E, Cihanbeylerden M, Tuccar C, Pehlivanlar Ustaoglu A, Cayiroz K, et al. Clinical outcomes and risk factors associated with breakthrough reactions in chemotherapy desensitization. Allergy Asthma Proc. 2026;47(3):216\u201324. https:\/\/doi.org\/10.2500\/aap.2026.47.260018.","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"1298_CR69","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.anai.2025.11.019","volume":"136","author":"J Gil-Serrano","year":"2026","unstructured":"Gil-Serrano J, Galvan-Blasco P, Pereira-Gonzalez J, Guilarte M, Luengo O, Sala-Cunill A, et al. Update on desensitization to chemotherapeutics and biologicals. Ann Allergy Asthma Immunol. 2026;136(4):422\u20133. https:\/\/doi.org\/10.1016\/j.anai.2025.11.019.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"1298_CR70","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s40521-022-00312-7","volume":"9","author":"R Madrigal-Burgaleta","year":"2022","unstructured":"Madrigal-Burgaleta R, Guzman-Melendez MA, Alvarez-Cuesta E. New Technical Aspects Used in the Management of Desensitization to Antineoplastic Drugs. Curr Treat Options Allergy. 2022;9(3):204\u201318. https:\/\/doi.org\/10.1007\/s40521-022-00312-7.","journal-title":"Curr Treat Options Allergy"},{"key":"1298_CR71","doi-asserted-by":"publisher","first-page":"1751512","DOI":"10.3389\/falgy.2026.1751512","volume":"7","author":"MC Torres Gorriz","year":"2026","unstructured":"Torres Gorriz MC, Borras Cuartero J, Viedma Ayllon P, Sanchez Hernandez A, Vergara Hernandez C, Gil Viciano I, et al. Comparison of rapid and same-day desensitization protocols in hypersensitivity reactions to platinum and taxanes: a retrospective cohort study. Front Allergy. 2026;7:1751512. https:\/\/doi.org\/10.3389\/falgy.2026.1751512.","journal-title":"Front Allergy"},{"issue":"5","key":"1298_CR72","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jaip.2024.03.021","volume":"12","author":"AM Copaescu","year":"2024","unstructured":"Copaescu AM, Li L, Blumenthal KG, Trubiano JA. How to Define and Manage Low-Risk Drug Allergy Labels. J Allergy Clin Immunol Pract. 2024;12(5):1095\u2013106. https:\/\/doi.org\/10.1016\/j.jaip.2024.03.021.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"1298_CR73","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/all.15113","volume":"77","author":"M Pagani","year":"2022","unstructured":"Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, et al. Hypersensitivity reactions to chemotherapy: an EAACI Position Paper. Allergy. 2022;77(2):388\u2013403. https:\/\/doi.org\/10.1111\/all.15113.","journal-title":"Allergy"},{"issue":"6","key":"1298_CR74","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1111\/pai.70136","volume":"36","author":"JR Brozyna","year":"2025","unstructured":"Brozyna JR, Patel R, Fancher WB, Anderson J, CaJacob A. Omalizumab pretreatment in a case of pediatric carboplatin desensitization. Pediatr Allergy Immunol. 2025;36(6):e70136. https:\/\/doi.org\/10.1111\/pai.70136.","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"1298_CR75","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s13023-025-03844-8","volume":"20","author":"F Spataro","year":"2025","unstructured":"Spataro F, Solimando AG, Desantis V, Vacca A, Di Girolamo A, Ria R. How to manage hypersensitivity reactions to enzyme replacement therapy in lysosomal storage diseases? Orphanet J Rare Dis. 2025;20(1):287. https:\/\/doi.org\/10.1186\/s13023-025-03844-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"1298_CR76","doi-asserted-by":"publisher","first-page":"e70277","DOI":"10.1111\/pai.70277","volume":"37","author":"F Mori","year":"2026","unstructured":"Mori F, Atanaskovic-Markovic M, Barbaud A, Bavbek S, Caubet JC, de Las Vecillas L, et al. Immediate and delayed hypersensitivity to biologicals in children-A practical approach: An EAACI task force report. Pediatr Allergy Immunol. 2026;37(4):e70277. https:\/\/doi.org\/10.1111\/pai.70277.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"1298_CR77","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/pai.13034","volume":"30","author":"M Atanaskovic-Markovic","year":"2019","unstructured":"Atanaskovic-Markovic M, Gomes E, Cernadas JR, du Toit G, Kidon M, Kuyucu S, et al. Diagnosis and management of drug-induced anaphylaxis in children: An EAACI position paper. Pediatr Allergy Immunol. 2019;30(3):269\u201376. https:\/\/doi.org\/10.1111\/pai.13034.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3","key":"1298_CR78","doi-asserted-by":"publisher","first-page":"e13759","DOI":"10.1111\/pai.13759","volume":"33","author":"S Esenboga","year":"2022","unstructured":"Esenboga S, Akarsu A, Ocak M, Gur Cetinkaya P, Sahiner UM, Sekerel BE, et al. Safety and efficacy of rapid drug desensitization in children. Pediatr Allergy Immunol. 2022;33(3):e13759. https:\/\/doi.org\/10.1111\/pai.13759.","journal-title":"Pediatr Allergy Immunol"},{"issue":"3\u2013S","key":"1298_CR79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.23750\/abm.v90i3-S.8158","volume":"90","author":"S Caimmi","year":"2019","unstructured":"Caimmi S, Caffarelli C, Saretta F, Liotti L, Crisafulli G, Cardinale F, et al. Drug desensitization in allergic children. Acta Biomed. 2019;90(3\u2013S):20\u20139. https:\/\/doi.org\/10.23750\/abm.v90i3-S.8158.","journal-title":"Acta Biomed"}],"container-title":["Current Allergy and Asthma Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11882-026-01298-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11882-026-01298-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:02:06Z","timestamp":1790636526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11882-026-01298-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1007\/s11882-026-01298-x","relation":{},"ISSN":["1534-6315"],"issn-type":[{"value":"1534-6315","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"12 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"53"}}